168 related articles for article (PubMed ID: 34141070)
1. Site-specific Incorporation of 2',5'-Linked Nucleic Acids Enhances Therapeutic Profile of Antisense Oligonucleotides.
Prakash TP; Yu J; Shen W; De Hoyos CL; Berdeja A; Gaus H; Liang XH; Crooke ST; Seth PP
ACS Med Chem Lett; 2021 Jun; 12(6):922-927. PubMed ID: 34141070
[TBL] [Abstract][Full Text] [Related]
2. Site-specific incorporation of 5'-methyl DNA enhances the therapeutic profile of gapmer ASOs.
Vasquez G; Freestone GC; Wan WB; Low A; De Hoyos CL; Yu J; Prakash TP; Ǿstergaard ME; Liang XH; Crooke ST; Swayze EE; Migawa MT; Seth PP
Nucleic Acids Res; 2021 Feb; 49(4):1828-1839. PubMed ID: 33544849
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Phosphorus and Non-Phosphorus Neutral Oligonucleotide Backbones for Enhancing Therapeutic Index of Gapmer Antisense Oligonucleotides.
Vasquez G; Migawa MT; Wan WB; Low A; Tanowitz M; Swayze EE; Seth PP
Nucleic Acid Ther; 2022 Feb; 32(1):40-50. PubMed ID: 34698585
[TBL] [Abstract][Full Text] [Related]
4. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP
Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820
[TBL] [Abstract][Full Text] [Related]
5. Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins.
Migawa MT; Shen W; Wan WB; Vasquez G; Oestergaard ME; Low A; De Hoyos CL; Gupta R; Murray S; Tanowitz M; Bell M; Nichols JG; Gaus H; Liang XH; Swayze EE; Crooke ST; Seth PP
Nucleic Acids Res; 2019 Jun; 47(11):5465-5479. PubMed ID: 31034558
[TBL] [Abstract][Full Text] [Related]
6. The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2'-
Zhang L; Liang XH; De Hoyos CL; Migawa M; Nichols JG; Freestone G; Tian J; Seth PP; Crooke ST
Nucleic Acid Ther; 2022 Oct; 32(5):401-411. PubMed ID: 35861704
[TBL] [Abstract][Full Text] [Related]
7. Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides.
Anderson BA; Freestone GC; Low A; De-Hoyos CL; Iii WJD; Østergaard ME; Migawa MT; Fazio M; Wan WB; Berdeja A; Scandalis E; Burel SA; Vickers TA; Crooke ST; Swayze EE; Liang X; Seth PP
Nucleic Acids Res; 2021 Sep; 49(16):9026-9041. PubMed ID: 34417625
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
[TBL] [Abstract][Full Text] [Related]
9. Systematic Analysis of Chemical Modifications of Phosphorothioate Antisense Oligonucleotides that Modulate Their Innate Immune Response.
Pollak AJ; Zhao L; Crooke ST
Nucleic Acid Ther; 2023 Apr; 33(2):95-107. PubMed ID: 36749166
[TBL] [Abstract][Full Text] [Related]
10. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
[TBL] [Abstract][Full Text] [Related]
11. Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides.
Yoshida T; Morihiro K; Naito Y; Mikami A; Kasahara Y; Inoue T; Obika S
Nucleic Acids Res; 2022 Jul; 50(13):7224-7234. PubMed ID: 35801870
[TBL] [Abstract][Full Text] [Related]
12. Dynamic and static control of the off-target interactions of antisense oligonucleotides using toehold chemistry.
Terada C; Oh K; Tsubaki R; Chan B; Aibara N; Ohyama K; Shibata MA; Wada T; Harada-Shiba M; Yamayoshi A; Yamamoto T
Nat Commun; 2023 Dec; 14(1):7972. PubMed ID: 38042877
[TBL] [Abstract][Full Text] [Related]
13. Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.
Shen W; De Hoyos CL; Sun H; Vickers TA; Liang XH; Crooke ST
Nucleic Acids Res; 2018 Mar; 46(5):2204-2217. PubMed ID: 29390093
[TBL] [Abstract][Full Text] [Related]
14. Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells.
Wang S; Allen N; Prakash TP; Liang XH; Crooke ST
Nucleic Acid Ther; 2019 Oct; 29(5):245-255. PubMed ID: 31158063
[TBL] [Abstract][Full Text] [Related]
15. Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins.
Hyjek-Składanowska M; Vickers TA; Napiórkowska A; Anderson BA; Tanowitz M; Crooke ST; Liang XH; Seth PP; Nowotny M
J Am Chem Soc; 2020 Apr; 142(16):7456-7468. PubMed ID: 32202774
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
[TBL] [Abstract][Full Text] [Related]
17. Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals.
Seth PP; Jazayeri A; Yu J; Allerson CR; Bhat B; Swayze EE
Mol Ther Nucleic Acids; 2012 Sep; 1(10):e47. PubMed ID: 23344239
[TBL] [Abstract][Full Text] [Related]
18. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
[TBL] [Abstract][Full Text] [Related]
19. Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides.
Wang S; Sun H; Tanowitz M; Liang XH; Crooke ST
Nucleic Acids Res; 2017 May; 45(9):5309-5322. PubMed ID: 28379543
[TBL] [Abstract][Full Text] [Related]
20. Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides.
Wang S; Allen N; Liang XH; Crooke ST
Mol Ther Nucleic Acids; 2018 Dec; 13():686-698. PubMed ID: 30508785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
